

North America Hemostats Market

<https://marketpublishers.com/r/N8587C869CBEN.html>

Date: September 2017

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: N8587C869CBEN

Abstracts

In this region, North America hemostats market is projected to reach USD 2,608.4 million by 2024, from USD 1,575.2 million in 2016 growing at a CAGR of 6.5% in the forecast period 2017 to 2024.

Based on geography, the North America hemostats market is segmented into 3 geographical regions, such as,

U.S.,

Mexico,

Canada

North America hemostats market competition by top players including

Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as

Baxter,

Vascular Solutions, Inc.,

B.Braun Melsungen,

3-D Matrix, Ltd.,

Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company),

Anika Therapeutics, Inc.,

Arch Therapeutics Inc.,

Biom'Up SAS,

CryoLife, Inc.,

Gamma Therapeutics, Inc.,

Hemostasis, LLC,

MedTrade Products Limited, I

Integra LifeSciences Corporation,

Medline Industries, Inc.,

HEMOTEC MEDICAL GMBH,

Stryker,

CSL Behring,

Mallinckrodt,

Equimedical, B.V.

The North America hemostats market is segmented on the basis of type, application, distribution channel, and end user.

The North America hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics.

Contents

1. INTRODUCTION

- 1.1. OBJECTIVES OF THE STUDY
- 1.2. MARKET DEFINITION
- 1.3. OVERVIEW OF NORTH AMERICA HEMOSTATS MARKET
- 1.4. CURRENCY AND PRICING
- 1.5. LIMITATION
- 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

- 2.1. MARKETS COVERED
- 2.2. GEOGRAPHIC SCOPE
- 2.3. YEARS CONSIDERED FOR THE STUDY
- 2.4. CURRENCY AND PRICING
- 2.5. RESEARCH METHODOLOGY
- 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.7. SECONDARY SOURCE
- 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

- 3.1. DRIVERS
 - 3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
 - 3.1.2. TECHNOLOGICAL ADVANCEMENTS
 - 3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
 - 3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING
- 3.2. RESTRAINTS
 - 3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
 - 3.2.2. WEAK REIMBURSEMENT
- 3.3. OPPORTUNITIES
 - 3.3.1. UNMET MEDICAL NEEDS
 - 3.3.2. EMERGING MARKET
- 3.4. CHALLENGES
 - 3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS

3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW

5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW

6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. NORTH AMERICA HEMOSTATS MARKET, BY TYPE

8.1. OVERVIEW

8.2. THROMBIN BASED HEMOSTATS

8.3. COMBINATION AGENT HEMOSTATS

8.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS

8.5. GELATIN BASED HEMOSTATS

8.6. COLLAGEN BASED HEMOSTATS

9. NORTH AMERICA HEMOSTATS MARKET, BY APPLICATION

9.1. OVERVIEW

9.2. NORTH AMERICA HEMOSTATS MARKET, BY APPLICATION

9.3. WOUND CLOSURE

9.4. SURGICAL HEMOSTATS

10. NORTH AMERICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW

10.1.1. DIRECT TENDERS

10.1.2. RETAIL

11. NORTH AMERICA HEMOSTATS MARKET, BY END USER

- 11.1. OVERVIEW
- 11.2. HOSPITALS
- 11.3. AMBULATORY CENTERS
- 11.4. COMMUNITY HEALTHCARE
- 11.5. CLINICS

12. NORTH AMERICA HEMOSTATS MARKET, BY GEOGRAPHY

- 12.1. OVERVIEW
- 12.2. NORTH AMERICA
 - 12.2.1. U.S.
 - 12.2.2. CANADA
 - 12.2.3. MEXICO

13. NORTH AMERICA HEMOSTATS MARKET, COMPANY LANDSCAPE

- 13.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
- 13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
- 13.3. COMPANY SHARE ANALYSIS: EUROPE
- 13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

- 14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC)
 - 14.1.1. COMPANY OVERVIEW
 - 14.1.2. REVENUE ANALYSIS
 - 14.1.3. PRODUCT PORTFOLIO
 - 14.1.4. RECENT DEVELOPMENTS
- 14.2. PFIZER
 - 14.2.1. COMPANY OVERVIEW
 - 14.2.2. REVENUE ANALYSIS
 - 14.2.3. PRODUCT PORTFOLIO
 - 14.2.4. RECENT DEVELOPMENTS
- 14.3. C.R BARD
 - 14.3.1. COMPANY OVERVIEW
 - 14.3.2. REVENUE ANALYSIS
 - 14.3.3. PRODUCT PORTFOLIO

14.3.4. RECENT DEVELOPMENTS

14.4. BAXTER

14.4.1. COMPANY OVERVIEW

14.4.2. REVENUE ANALYSIS

14.4.3. PRODUCT PORTFOLIO

14.4.4. RECENT DEVELOPMENTS

14.5. VASCULAR SOLUTIONS, INC

(ACQUIRED BY TELEFLEX INCORPORATED)

14.5.1. COMPANY OVERVIEW

14.5.2. REVENUE ANALYSIS

14.5.3. PRODUCT PORTFOLIO

14.5.4. RECENT DEVELOPMENTS

14.6. B.BRAUN MELSUNGEN AG

14.6.1. COMPANY OVERVIEW

14.6.2. REVENUE ANALYSIS

14.6.3. PRODUCT PORTFOLIO

14.6.4. RECENT DEVELOPMENTS

14.7. 3-D MATRIX LTD

14.7.1. COMPANY OVERVIEW

14.7.2. REVENUE ANALYSIS

14.7.3. PRODUCT PORTFOLIO

14.7.4. RECENT DEVELOPMENTS

14.8. RESORBA MEDICAL GMBH

14.8.1. COMPANY OVERVIEW

14.8.2. REVENUE ANALYSIS

14.8.3. PRODUCT PORTFOLIO

14.8.4. RECENT DEVELOPMENTS

14.9. ANIKA THERAPEUTICS, INC.

14.9.1. COMPANY OVERVIEW

14.9.2. REVENUE ANALYSIS

14.9.3. PRODUCT PORTFOLIO

14.9.4. RECENT DEVELOPMENTS

14.10. BIOM'UP

14.10.1. COMPANY OVERVIEW

14.10.2. REVENUE ANALYSIS

14.10.3. PRODUCT PORTFOLIO

14.10.4. RECENT DEVELOPMENTS

14.11. CRYOLIFE, INC.

14.11.1. COMPANY OVERVIEW

- 14.11.2. REVENUE ANALYSIS
- 14.11.3. PRODUCT PORTFOLIO
- 14.11.4. RECENT DEVELOPMENTS
- 14.12. EQUIMEDICAL
 - 14.12.1. COMPANY OVERVIEW
 - 14.12.2. REVENUE ANALYSIS
 - 14.12.3. PRODUCT PORTFOLIO
 - 14.12.4. RECENT DEVELOPMENTS
- 14.13. HEMOSTASIS, LLC
 - 14.13.1. COMPANY OVERVIEW
 - 14.13.2. REVENUE ANALYSIS
 - 14.13.3. PRODUCT PORTFOLIO
 - 14.13.4. RECENT DEVELOPMENTS
- 14.14. MEDTRADE PRODUCTS LIMITED
 - 14.14.1. COMPANY OVERVIEW
 - 14.14.2. REVENUE ANALYSIS
 - 14.14.3. PRODUCT PORTFOLIO
 - 14.14.4. RECENT DEVELOPMENTS
- 14.15. STRYKER
 - 14.15.1. COMPANY OVERVIEW
 - 14.15.2. REVENUE ANALYSIS
 - 14.15.3. PRODUCT PORTFOLIO
 - 14.15.4. RECENT DEVELOPMENTS
- 14.16. ARCH THERAPEUTICS, INC.
 - 14.16.1. COMPANY OVERVIEW
 - 14.16.2. REVENUE ANALYSIS
 - 14.16.3. PRODUCT PORTFOLIO
 - 14.16.4. RECENT DEVELOPMENTS
- 14.17. INTEGRA LIFESCIENCES CORPORATION
 - 14.17.1. COMPANY OVERVIEW
 - 14.17.2. REVENUE ANALYSIS
 - 14.17.3. PRODUCT PORTFOLIO
 - 14.17.4. RECENT DEVELOPMENTS
- 14.18. ALTAYLAR MEDICAL
 - 14.18.1. COMPANY OVERVIEW
 - 14.18.2. REVENUE ANALYSIS
 - 14.18.3. PRODUCT PORTFOLIO
 - 14.18.4. RECENT DEVELOPMENTS
- 14.19. BIOCER ENTWICKLUNGS-GMBH

- 14.19.1. COMPANY OVERVIEW
- 14.19.2. REVENUE ANALYSIS
- 14.19.3. PRODUCT PORTFOLIO
- 14.19.4. RECENT DEVELOPMENTS
- 14.20. SMI (STARCH MEDICAL)
 - 14.20.1. COMPANY OVERVIEW
 - 14.20.2. REVENUE ANALYSIS
 - 14.20.3. PRODUCT PORTFOLIO
 - 14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

TABLE LIST

TABLE 1 NORTH AMERICA HEMOSTATSMARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)

TABLE 2 NORTH AMERICA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 3 NORTH AMERICA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 4 NORTH AMERICA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)

TABLE 5 NORTH AMERICA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

TABLE 6 U.S. HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 7 U.S. HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 8 U.S. HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)

TABLE 9 U.S. HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

TABLE 10 CANADA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 11 CANADA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 12 CANADA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)

TABLE 13 CANADA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

TABLE 14 MEXICO HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

TABLE 15 MEXICO HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 16 MEXICO HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)

TABLE 17 MEXICO HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

Figures

FIGURES LIST

FIGURE 1 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR HEMOSTATS AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR

IN THE FORECAST PERIOD TO 2024

FIGURE 2 NORTH AMERICA HEMOSTATS MARKET SNAPSHOT (2017)

FIGURE 3 NORTH AMERICA HEMOSTATS MARKET: BY GEOGRAPHY (2016)

FIGURE 4 NORTH AMERICA HEMOSTATSMARKET:BY COUNTRY (2017)

FIGURE 5 NORTH AMERICA HEMOSTATS MARKET BY COUNTRY (2016 & 2024)

FIGURE 6 NORTH AMERICA HEMOSTATS MARKET BY PRODUCT TYPE (2017 & 2024)

FIGURE 7 NORTH AMERICA HEMOSTATS MARKET: COMPANY SHARE 2016 (%)

COMPNIES PROFILES

Baxter, Vascular Solutions, Inc., B.Braun Melsungen, 3-D Matrix, Ltd., Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company), Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom'Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC

I would like to order

Product name: North America Hemostats Market

Product link: <https://marketpublishers.com/r/N8587C869CBEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N8587C869CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970